Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

BACKGROUND: Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell death ligand 1 (PD‐L1). However, no direct comparison da...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Med
Main Authors: Zhou, Yixin, Zhang, Yaqiong, Guo, Guifang, Cai, Xiuyu, Yu, Hui, Cai, Yanyu, Zhang, Bei, Hong, Shaodong, Zhang, Li
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240850/
https://ncbi.nlm.nih.gov/pubmed/32508007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados